Immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) has been a staple treatment for non-muscle-invasive bladder cancer (NMIBC) for several decades. More recently, immune checkpoint inhibitors (ICIs) have been incorporated into the standard of care for urothelial cancer (a term that encompasses cancers of the bladder, urethra, and upper urinary tract) across all stages of the disease. To provide guidance to urologists amidst a rapidly evolving treatment landscape, the Society for Immunotherapy of Cancer (SITC)—the world’s leading member-driven organization devoted to advancing the science and application of cancer immunotherapy—convened a panel of experts to update the society’s 2017 clinical practice guideline.1 The new manuscript, “Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for the treatment of urothelial cancer,” provides recommendations on approved indications for use of BCG and ICIs, emerging immunotherapy strategies including neo/adjuvant approaches and novel combinations, biomarker testing, patient education and quality of life, and more.2